The Mechanism of Action of Olaparib
Jane Robertson, MD, Global Product Vice President at AstraZeneca, describes the mechanism of action of the PARP inhibitor olaparib.
Jane Robertson, MD, Global Product Vice President of Oncology at AstraZeneca, describes the mechanism of action of olaparib, a PARP inhibitor.
The enzyme PARP is important for repairing single strand DNA breaks. If PARP is inhibited, single strand breaks cannot be repaired efficiently. Robertson explains that as the cell goes through cell division, these breaks become double strand breaks, which are lethal to cells, Robertson says. Eventually, this causes cumulative DNA damage and the cell dies.
Clinical Pearls
Normal cells, however, have a good pathway (the homologous recombination pathway) to repair double strand breaks. Some types of tumor cells have a deficiency in this homologous recombination pathway. Robertson said the best example of this phenomenon is the deficiencies that can occur in BRCA1 and BRCA2.
- Olaparib is a PARP inhibitor
- Inhibiting PARP causes cumulative DNA damage and cell death
- Some types of tumor cells have a deficiency in the homologous recombination pathway
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
